THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a ...

Ascension Wisconsin recently honored Racine paramedics and the Ascension All Saints Hospital Emergency Department for their ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

FDA approval was based on the AcT noninferiority trial that found tenecteplase (at 0.25 mg/kg) to be at least on par with alteplase for safety and efficacy in acute ischemic stroke in Canadians ...

Genentech, part of the Roche (ROG SIX) group, has received a new approval from the US Food and Drug Administration for TNKase ...